The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2016
DOI: 10.1097/anc.0000000000000244
|View full text |Cite
|
Sign up to set email alerts
|

Neonatal Extracorporeal Membrane Oxygenation

Abstract: With the overall decreasing use of neonatal ECMO, ECMO centers must find ways to maintain their expertise in the light of lower patient volumes amidst complex patient physiology.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 24 publications
(4 citation statements)
references
References 83 publications
0
4
0
Order By: Relevance
“…ECMO is a well-established advanced life support therapy for critically-ill children with pulmonary or cardiac failure (1). It involves technically challenging procedures and extensive multidisciplinary coordination.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…ECMO is a well-established advanced life support therapy for critically-ill children with pulmonary or cardiac failure (1). It involves technically challenging procedures and extensive multidisciplinary coordination.…”
Section: Discussionmentioning
confidence: 99%
“…Extracorporeal membrane oxygenation (ECMO) is an advanced life support therapy for life-threatening pulmonary and cardiac diseases in children (1). ECMO is a high-risk procedure and requires quick and effective decisions based on well-established knowledge as well as technical and organizational proficiency in an emergency setting (2).…”
Section: Introductionmentioning
confidence: 99%
“…It was the same mortality rate as reported by the ELSO Registry in 2012 [ 39 ]. The proportion of neonates requiring ECMO has declined but the mortality rates for neonates supported on ECMO have increased [ 40 , 41 ].…”
Section: Discussionmentioning
confidence: 99%
“…Anticoagulation during ECMO was achieved by continuous heparin infusion up to 30 IE/kg/h and monitored by measuring regularly (twice a day) the activated clotting time (ACT), targeted between 150 and 200 s depending on the individual bleeding risk of a patient ( 5 ). Other coagulation parameters were also monitored routinely as consumptive coagulopathy frequently occurred during ECMO, especially within the first 24 h. For a detailed description of the physiology and clinical use of neonatal ECMO, we refer to the literature ( 6 ).…”
Section: Ecmo-system and Cannulationmentioning
confidence: 99%